Sanara MedTech Inc. (NASDAQ:SMTI ) Q4 2024 Earnings Conference Call March 25, 2025 8:00 AM ET Company Participants Ron Nixon - Executive Chairman and Chief Executive Officer Seth Yon - President, Commercial Sam Muppalla - Tissue Health Plus Tyler Palmer - Chief Corporate Development and Strategy Officer Elizabeth Taylor - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor...
Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the su...
FORT WORTH, TX, March 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its fourth quarter and full year ...
Shares have risen nearly 15% since the company posted preliminary Q4 results, which showed revenue up by 45-48% year over year. While growth was boosted by one-off demand for its BIASURGE product, underlying growth was still strong at 37%. There remains a long runway for growth for its surgical products, with the potential for this to be augmented by other growth drivers, including inorganic op...
SHANNON, Ireland, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Irish medical device company Biomimetic Innovations Limited, an affiliate of PBC Biomed, today announced the execution of an exclusive license and distribution agreement with Sanara MedTech Inc (“Sanara”) (Nasdaq:SMTI). In tandem, Sanara agreed to make a minority investment in cash for equity in BMI.
OsStic ® and related technologies represent differentiated solutions that address an estimated 100,000+ procedures in the U.S. annually ( 1) ; arrangement leverages Sanara's existing call points and commercial infrastructure, and complements Sanara's existing surgical portfolio
Fourth Quarter Net Revenue Expected to Increase 45% to 48% Year-Over-Year; Full Year Net Revenue Expected to Increase 32% to 33% Year-Over-Year
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.